Featured Research

from universities, journals, and other organizations

Skin transplant offers new hope to vitiligo patients

Date:
March 10, 2010
Source:
Henry Ford Health System
Summary:
A new study finds that skin transplant surgery is safe and effective for treating vitiligo. Researchers followed 23 patients for up to six months after surgery and found that the treated area regained on average 52 percent of its natural skin color. In eight patients with a specific type of vitiligo, the treated area regained on average 74 percent of its natural skin color.

Skin Transplant for Vitiligo -- Top: Vitiligo before MKTP surgery. Bottom: Vitiligo after MKTP surgery.
Credit: Henry Ford Hospital

In the first study of its kind in the United States, Henry Ford Hospital showed that skin transplant surgery is safe and effective for treating vitiligo.

Related Articles


Henry Ford researchers followed 23 patients for up to six months after surgery and found that the treated area regained on average 52 percent of its natural skin color. In eight patients with a specific type of vitiligo, the treated area regained on average 74 percent of its natural skin color.

The surgery involves using skin cells taken from normally-pigmented areas of the body and transferring them to the damaged area of skin. It is performed under local anesthesia.

"This surgery offers hope to vitiligo patients," says Iltefat Hamzavi, M.D. a senior staff physician in Henry Ford's Department of Dermatology and the study's senior author and principal investigator. "The results achieved in our study were of obvious significance to our patients."

The study are being presented at the 68th annual American Academy of Dermatology meeting in Miami.

While the initial results are preliminary and the procedure is still investigational, Dr. Hamzavi says Henry Ford hopes to offer the surgery as part of its treatment portfolio this fall. He says for some patients the surgery is more effective than standard treatments like light therapy and topical medications.

"Patients of color and those with vitiligo on one side of the body and in one area of the body may benefit most from this procedure," Dr. Hamzavi says.

Vitiligo is a skin disease that causes the skin to lose color and develop white patches that vary in size and location. It affects about 1 in every 200 people in the United States, and is more noticeable in people with darker skin.

Vitiligo develops when cells called melanocytes are killed by the body's immune system, causing the area of skin to turn white because the cells no longer make pigment. While there is no cure, vitiligo can be treated and managed with light therapy, creams and topical medications.

The surgery is known as melanocyte-keratinocyte transplantation or MKTP, and is performed in Europe, Asia and Middle East. It was performed at Henry Ford using the same technique developed by MKTP pioneer Sanjeev Mulekar, M.D., of the National Vitiligo Center in Saudi Arabia. Henry Ford is the first to perform MKTP in North America.

In Henry Ford's study, 32 patients (18 male, 14 female) underwent surgery and ranged in age from 18 to 60. A total of 40 MKTP procedures were performed and researchers analyzed the outcomes of 29 of them. A procedure lasted 30 minutes to two hours and patients returned home the same day.

Of the 32 surgery patients, 23 were followed for up to six months after surgery. Eighteen patients received one treatment, four patients received two and one patient received three. The ethnicity of patients was Caucasian, South Asian, African American and Hispanic.

During MKTP, melanocyte cells, which produce pigment in the skin, hair and eyes, are harvested from an area of healthy skin and separated to make a skin cell mixture. This mixture then is applied to the treatment area and covered with a specially developed adhesive biologic dressing.

Treated areas included the hands, arms, legs, feet, face and stomach. The average size of the treated area during each procedure covered an area of 46 cm2, or roughly the size of a credit card.

The study was a collaboration with the National Center for Vitiligo, Riyadh, Saudi Arabia, and funded by the Shahani Foundation based in Michigan.


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Cite This Page:

Henry Ford Health System. "Skin transplant offers new hope to vitiligo patients." ScienceDaily. ScienceDaily, 10 March 2010. <www.sciencedaily.com/releases/2010/03/100309142749.htm>.
Henry Ford Health System. (2010, March 10). Skin transplant offers new hope to vitiligo patients. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2010/03/100309142749.htm
Henry Ford Health System. "Skin transplant offers new hope to vitiligo patients." ScienceDaily. www.sciencedaily.com/releases/2010/03/100309142749.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins